Statistics of melanoma in Japan : Analysis of a 2006-2007 nationwide survey and a 2005-2010 follow-up survey

康弘, 藤澤; 藤男, 大塚; 明史, 山本; 直也, 山﨑; 俊明, 斎田; 和之, 石原

doi:10.5227/skincancer.27.195

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of diagnosed Japanese OCA patients is approximately 5000, and MM occurred in 11 of these patients during a 35-year period. Therefore, the annual ratio of MM development in OCA patients is estimated to be approximately 1/16,000, whereas that in the general population is estimated to be 1/100,000 [38]. In fact, we recently identified an association between another decrease-offunction polymorphism in the P gene and the occurrence of MM .…”

Section: Discussionmentioning

confidence: 99%

Malignant Skin Tumors in Patients with Oculocutaneous Albinism

Nishigori¹,

Takata²,

Suzuki³

2015

Pigmentary Disorders

View full text Add to dashboard Cite

Background:Patients with oculocutaneous albinism (OCA) are prone to develop skin cancers. Aim and Objectives:To analyze reports of skin cancers in albinos published in the English and the Japanese literature in order to prepare guidelines for the successful management of skin cancer in albinos. Methods and Materials:We searched on PubMed, Web of Knowledge for English literature, and Ichushi-Web for the Japanese literature. Results:Between 1978 and 2013, 11 malignant melanoma, 4 basal cell carcinoma, and 6 squamous cell carcinoma cases were reported in Japan. The subtypes of the 11 malignant melanomas were nodular in 7 cases, superficial spreading in 3 cases, and metastatic lesions in 1 case. Amelanotic melanomas comprised 7 of the 11 malignant melanoma cases in Japanese patients with OCA. Twenty-five malignant melanoma, 50 basal cell carcinoma, and 151 squamous cell carcinoma cases were reported worldwide in the English literature during the period between 1952 and 2013.Conclusion: Regular skin monitoring by board-certified dermatologists is required for adult OCA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Skin Tumors in Patients with Oculocutaneous Albinism

Nishigori¹,

Takata²,

Suzuki³

2015

Pigmentary Disorders

View full text Add to dashboard Cite

show abstract

“…The effectiveness of these postoperative adjuvant therapies was analyzed using data obtained from a national follow-up survey conducted by the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society. Long-term IFN therapy significantly improved survival in all cancer stages, whereas DAVFeron therapy and IFN therapy showed no effect [ 5 , 6 ]. However, some questions remain to be answered.…”

Section: Discussionmentioning

confidence: 99%

A Case of Malignant Melanoma with In-Transit Metastasis That Responded to Intravenous Infusion of Interferon-β

et al. 2014

View full text Add to dashboard Cite

A 77-year-old man with a history of surgical resection of malignant melanoma involving the fifth toe of his left foot 14 years ago presented at the Kariya Toyota General Hospital with a 3-month history of skin ulcer at the same site and red nodules on the lower left leg. Malignant melanoma was suspected, and the patient was referred to our department. On examination, a skin ulcer measuring 25 × 20 mm was observed at the amputation site on the left foot. In addition, multiple red nodules were observed on the lower left leg. Skin biopsies of the ulcer and nodules revealed recurrent malignant melanoma with in-transit metastasis. Two weeks later, he developed acute myocardial infarction and was hospitalized at the Kariya Toyota General Hospital. One month later, the myocardial infarction ameliorated, and he was transferred to our department. As the myocardial infarction had decreased the patient's tolerance to surgery, interferon-β was administered by intravenous infusion. The skin ulcer and red nodules on the lower left leg disappeared 26 weeks after infusion had been initiated. The patient's progress has been satisfactory, with no evidence of recurrence or metastasis at 1 year and 9 months after the initiation of intravenous infusion.

show abstract